Supernus Pharmaceuticals, Inc. $SUPN Shares Bought by Profund Advisors LLC

Profund Advisors LLC increased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 351.2% during the third quarter, Holdings Channel.com reports. The firm owned 39,129 shares of the specialty pharmaceutical company’s stock after buying an additional 30,456 shares during the quarter. Profund Advisors LLC’s holdings in Supernus Pharmaceuticals were worth $1,684,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. BlackRock Inc. bought a new stake in Supernus Pharmaceuticals during the 2nd quarter valued at $434,871,000. Bank of America Corp DE boosted its stake in Supernus Pharmaceuticals by 37.2% during the 1st quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock valued at $36,918,000 after purchasing an additional 193,479 shares during the last quarter. Ashford Capital Management Inc. boosted its stake in Supernus Pharmaceuticals by 5.4% during the 1st quarter. Ashford Capital Management Inc. now owns 645,381 shares of the specialty pharmaceutical company’s stock valued at $33,360,000 after purchasing an additional 32,843 shares during the last quarter. Rice Hall James & Associates LLC boosted its stake in Supernus Pharmaceuticals by 2.0% during the 1st quarter. Rice Hall James & Associates LLC now owns 477,416 shares of the specialty pharmaceutical company’s stock valued at $24,678,000 after purchasing an additional 9,530 shares during the last quarter. Finally, Systematic Financial Management LP increased its holdings in Supernus Pharmaceuticals by 23.6% during the 1st quarter. Systematic Financial Management LP now owns 376,079 shares of the specialty pharmaceutical company’s stock worth $19,440,000 after purchasing an additional 71,853 shares in the last quarter.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock opened at $41.92 on Tuesday. Supernus Pharmaceuticals, Inc. has a 1 year low of $37.54 and a 1 year high of $59.68. The firm has a market cap of $2.44 billion, a PE ratio of -54.44, a P/E/G ratio of 1.21 and a beta of 0.55. The stock has a fifty day moving average price of $42.42 and a 200-day moving average price of $47.27.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.14). The company had revenue of $208.60 million during the quarter, compared to analysts’ expectations of $217.56 million. Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%. Supernus Pharmaceuticals’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.80) earnings per share. As a group, equities analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.79 EPS for the current fiscal year.

Supernus Pharmaceuticals Announces Dividend

The business also recently declared a special dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 30th will be paid a dividend of $8.13 per share.

Analyst Ratings Changes

A number of research firms have recently weighed in on SUPN. Zacks Research lowered Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, October 5th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings downgraded shares of Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a report on Friday. Finally, Cantor Fitzgerald upped their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus price target of $62.33.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.